No Data
China Merchants: Class B catalog will be released within the year + Commercial health Insurance provides additional payment for Innovative Drugs, further improving bulk purchasing and medical insurance prepayment.
The first version of the Category B directory is scheduled to be released within this year, and it is expected to be aligned with the annual adjustments of the medical insurance directory, contributing to the incremental increase of payments for Innovative Drugs.
Is China National Medicines Corporation Ltd.'s (SHSE:600511) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
China National Medicines Corporation Ltd.'s (SHSE:600511) Largest Shareholders Are Private Companies With 56% Ownership, Individual Investors Own 27%
China National Medicines Corporation (600511.SH): Chairman Jiang Xiuchang has retired and left office.
China National Medicines Corporation (600511.SH) announced that the board of directors recently received a submission from the company's chairman, Jiang Xiuchang, ...
Stocks are hitting the ceiling! Since October, 10 A-share listed companies have announced being targeted, with china national medicines corporation and sh pharma being targeted on the same day by new china life insurance.
① According to incomplete statistics, since October, 10 A-share listed companies including zhejiang east crystal electronic, semiconductor manufacturing international corporation, quanjinhao, lifecome biochemistry, zhejiang jingu, primeton information technologies, inc., guangzhou goaland energy conservation tech, xuzhou handler special vehicle, china national medicines corporation, and sh pharma have announced that they have received major stock purchases from relevant parties (see attached table). ② In the secondary market, this week, xuzhou handler special vehicle and guangzhou goaland energy conservation tech have both seen their stock prices increase by more than 100% since September.
Investors Don't See Light At End Of China National Medicines Corporation Ltd.'s (SHSE:600511) Tunnel
China National Medicines (SHSE:600511) Might Be Having Difficulty Using Its Capital Effectively
